Integra LifeSciences Holdings Corporation Common Stock (IART)
Stock · NASDAQ · Health Care
$13.23as of 10/16/2026
Price chart
IART Signal Track Record
How signals performed across all stocks →What IART's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 32 | -1.3% | 44% | October 2, 2026 |
| Bollinger Band Breakdown | 26 | -2.4% | 35% | October 2, 2026 |
| Bollinger Band Breakout | 20 | -2.4% | 45% | July 16, 2026 |
| 200-Day Moving Average TouchActive now | 9 | -4.9% | 44% | March 11, 2025 |
| Any 20-session window (baseline) | -2.7% | 42% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About IART
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates through Codman Specialty Surgical and Tissue Technologies segments. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cere…
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Employees
- 4,427
- Website
- www.integralife.com/
Fundamentals
- 1-day range
- $13.29$13.64
- Market cap
- $1.33B
- P/E (trailing)
- —
- P/E (forward)
- 5.32
- EPS (trailing)
- $-0.10
- Dividend yield
- —
- Beta
- 1.27
- Avg. volume
- 923.8K
How Integra LifeSciences Holdings Corporation Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 26, 2026 · via SEC EDGAR / Finnhub
Forecasts
9 analyst ratings
Integra LifeSciences Holdings Corporation Common Stock Competitors
Chosen by industry and closest market cap.
- IARTIntegra LifeSciences Holdings Corporation Common Stock$13.21▼ 2.37%Market cap $1.33BP/E —$8.7$20.49
- AORTArtivion Inc. Common Stock$21.78▼ 0.41%Market cap $1.29BP/E 117.64$19.16$48.25
- TNDMTandem Diabetes Care Inc. Common Stock$16.24▼ 1.69%Market cap $1.29BP/E —$12.26$29.65
- ATECAlphatec Holdings Inc. Common Stock$10.46▼ 4.30%Market cap $1.42BP/E —$6.82$23.29
- KMTSKestra Medical Technologies Ltd. Common Stock$27.24▼ 5.02%Market cap $1.48BP/E —$17.34$30
- BVSBioventus Inc. Class A Common Stock$13.3▼ 3.69%Market cap $1.17BP/E 21.32$6.46$15.89
- IRMDiRadimed Corporation Common Stock$88.27▼ 1.23%Market cap $1.17BP/E 49.82$71.34$107.9
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| IART Integra LifeSciences Holdings Corporation Common Stock | $1.33B | — | $13.21 | ▼ 2.37% | $8.7$20.49 |
| AORT Artivion Inc. Common Stock | $1.29B | 117.64 | $21.78 | ▼ 0.41% | $19.16$48.25 |
| TNDM Tandem Diabetes Care Inc. Common Stock | $1.29B | — | $16.24 | ▼ 1.69% | $12.26$29.65 |
| ATEC Alphatec Holdings Inc. Common Stock | $1.42B | — | $10.46 | ▼ 4.30% | $6.82$23.29 |
| KMTS Kestra Medical Technologies Ltd. Common Stock | $1.48B | — | $27.24 | ▼ 5.02% | $17.34$30 |
| BVS Bioventus Inc. Class A Common Stock | $1.17B | 21.32 | $13.3 | ▼ 3.69% | $6.46$15.89 |
| IRMD iRadimed Corporation Common Stock | $1.17B | 49.82 | $88.27 | ▼ 1.23% | $71.34$107.9 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
Insider Activity
Insider Actions →- Knight Lea Daniels · July 3, 2026 · Tax Withholding5.2K @ $18.05
- Singh Harvinder · July 1, 2026 · Grant5.6K
- Mosebrook Jeffrey · July 1, 2026 · Tax Withholding937 @ $17.89
- DAVIS ROBERT T. JR. · July 1, 2026 · Grant11.2K
- McBreen Michael J. · June 1, 2026 · Grant31.9K
- McBreen Michael J. · June 1, 2026 · Grant60.4K
- ESSIG STUART · June 1, 2026 · Grant365.3K
- ESSIG STUART · June 1, 2026 · Grant705.5K
- BRADLEY KEITH · May 9, 2026 · Tax Withholding882 @ $13.92
- Lo Renee Wonlai · May 7, 2026 · Grant17.7K
- Clay Shaundra · May 7, 2026 · Grant17.7K
- GRAVES JEFFREY A · May 7, 2026 · Grant17.7K
- HILL BARBARA B · May 7, 2026 · Grant17.7K
- HILL BARBARA B · May 7, 2026 · Grant6.6K
- SCHADE CHRISTIAN S · May 7, 2026 · Grant17.7K
Institutional Ownership
March 31, 2026
- Total shares held
- 69.74M
- Total value held
- $650.03M
- Institutional holders
- 193
- Unknown10.32M
- Unknown7.75M
- Unknown4.01M
- Unknown3.58M
- Unknown3.53M
- Unknown3.49M
- Unknown2.89M
- Unknown2.89M
- Unknown2.77M
- Unknown2.12M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Integra Focuses on ENT Portfolio; Analyst Target Cut to $15
Integra LifeSciences will showcase its ENT and instrument lines and sponsor new clinical research presentations at the AAO‑HNSF 2026 meeting. A recent analyst review lowered the price target to $15, reflecting a more cautious outlook. The company’s focus on ENT products comes amid a broader discussion of healthcare stocks that are of concern to investors.
Integra Focuses on ENT Portfolio; Analyst Target Cut to $15. Integra LifeSciences will showcase its ENT and instrument lines and sponsor new clinical research presentations at the AAO‑HNSF 2026 meeting. A recent analyst review lowered the price target to $15, reflecting a more cautious outlook. The company’s focus on ENT products comes amid a broader discussion of healthcare stocks that are of concern to investors.